You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Moodys
McKinsey
Dow
Baxter
Boehringer Ingelheim
Harvard Business School

Last Updated: September 27, 2020

DrugPatentWatch Database Preview

Details for Patent: 10,463,668

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which drugs does patent 10,463,668 protect, and when does it expire?

Patent 10,463,668 protects IMBRUVICA and is included in two NDAs.

This patent has eighteen patent family members in thirteen countries.

Summary for Patent: 10,463,668
Title:Methods of treating and preventing graft versus host disease
Abstract: Described herein are methods for treating and preventing graft versus host disease using ACK inhibitors. The methods include administering to an individual in need thereof an ACK inhibitor such as ibrutinib for treating and preventing graft versus host disease.
Inventor(s): Byrd; John C. (Columbus, OH), Dubovsky; Jason A. (Columbus, OH), Muthusamy; Natarajan (Columbus, OH), Johnson; Amy J. (Columbus, OH), Miklos; David (Stanford, CA)
Assignee: Pharmacyclics LLC (Sunnyvale, CA)
Application Number:15/586,058
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 10,463,668
Patent Claim Types:
see list of patent claims
 

Drugs Protected by US Patent 10,463,668

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Pharmacyclics Inc IMBRUVICA ibrutinib CAPSULE;ORAL 205552-002 Dec 20, 2017 RX Yes No   Start Trial   Start Trial TREATMENT OF REFRACTORY CHRONIC GRAFT-VERSUS-HOST DISEASE   Start Trial
Pharmacyclics Inc IMBRUVICA ibrutinib CAPSULE;ORAL 205552-001 Nov 13, 2013 RX Yes Yes   Start Trial   Start Trial TREATMENT OF REFRACTORY CHRONIC GRAFT-VERSUS-HOST DISEASE   Start Trial
Pharmacyclics Inc IMBRUVICA ibrutinib TABLET;ORAL 210563-001 Feb 16, 2018 RX Yes No   Start Trial   Start Trial TREATMENT OF REFRACTORY CHRONIC GRAFT-VERSUS-HOST DISEASE   Start Trial
Pharmacyclics Inc IMBRUVICA ibrutinib TABLET;ORAL 210563-002 Feb 16, 2018 RX Yes No   Start Trial   Start Trial TREATMENT OF REFRACTORY CHRONIC GRAFT-VERSUS-HOST DISEASE   Start Trial
Pharmacyclics Inc IMBRUVICA ibrutinib TABLET;ORAL 210563-003 Feb 16, 2018 RX Yes No   Start Trial   Start Trial TREATMENT OF REFRACTORY CHRONIC GRAFT-VERSUS-HOST DISEASE   Start Trial
Pharmacyclics Inc IMBRUVICA ibrutinib TABLET;ORAL 210563-004 Feb 16, 2018 RX Yes Yes   Start Trial   Start Trial TREATMENT OF REFRACTORY CHRONIC GRAFT-VERSUS-HOST DISEASE   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 10,463,668

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 098208   Start Trial
Australia 2014339815   Start Trial
Australia 2020204270   Start Trial
Canada 2928721   Start Trial
China 106102745   Start Trial
China 111265531   Start Trial
Eurasian Patent Organization 201690745   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Boehringer Ingelheim
Dow
Merck
Mallinckrodt
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.